Latest news with #STRO
Wales Online
3 days ago
- Wales Online
Woman charged in connection with child sexual exploitation and trafficking probe
Our community members are treated to special offers, promotions and adverts from us and our partners. You can check out at any time. More info A 52-year-old woman has been charged with multiple offences as part of an ongoing investigation into child sexual exploitation and trafficking. Sarah Gray, of Llanasa Road, Gronant, Flintshire, has been charged with conspiracy to supply Class A and Class B drugs, assisting an offender, and perverting the course of justice. She is due to appear at Mold Magistrates Court today (Friday, August 15). It follows an ongoing major investigation into child sexual exploitation and trafficking. Four Denbighshire men were recently charged with a series of offences - including rape, sexual assault, and the supply of illegal drugs. All four males will appear at Mold Crown Court on Friday, September 5. They are: Mustafa Iqbal, 42, of Trellewelyn Road, Rhyl, who is charged with three counts of rape, three counts of sexual assault, three counts of inciting a child aged under 16 to engage in sexual activity, six offences under Section 1 and 2 of the Modern Slavery Act, conspiracy to supply Class A and Class B drugs, possession of a firearm, and breach of a Slavery and Trafficking Risk Order (STRO). Mohammad Usman Arshad, 35, of Clifton Grove, Rhyl, who is charged with rape, four offences under Section 1 and 2 of the Modern Slavery Act, and the supply of Class B drugs. Ziaullah Badsha, 24, of Brighton Road, Rhyl, who is charged with two counts of rape, four offences under Section 1 and 2 of the Modern Slavery Act, and the supply of Class B drugs. Jaswinder Singh, 60, of River Street, Rhyl, who is charged with two offences under Section 2 of the Modern Slavery Act, and the supply of Class B drugs. A 61-year-old man from London, also arrested as part of the investigation, has been released on bail pending further enquiries. Operation Embank and Operation Zirconium are linked investigations that have been led by North Wales Police. The investigations involve three teenage females, who made reports in relation to a series of alleged offences in Rhyl and the surrounding area between April 2022 and March 2024. After the four men were charged, Detective Chief Inspector Rich Sidney, of North Wales Police, said: 'This has been a complex and long-running investigation. We have liaised with the Crown Prosecution Service throughout the process and this collaboration has resulted in authority to charge the suspects involved with multiple serious offences being provided. 'We would now ask for people to respect the judicial process and to avoid online speculation on this case. This is to ensure the integrity of the investigation and court proceedings.' Specialist Prosecutor Louisa Robertson at the CPS previously said: 'The Crown Prosecution Service has authorised North Wales Police to charge four males and one female in respect of these two investigations. 'The Crown Prosecution Service reminds all concerned that criminal proceedings against each individual are now active and that they all have a right to a fair trial. It is extremely important that there should be no reporting, commentary or sharing of information online which could in any way prejudice these proceedings.' Join the North Wales Live Whatsapp community now Find crime figures for your area
Yahoo
10-08-2025
- Business
- Yahoo
Sutro Biopharma Second Quarter 2025 Earnings: Beats Expectations
Sutro Biopharma (NASDAQ:STRO) Second Quarter 2025 Results Key Financial Results Revenue: US$63.7m (up 148% from 2Q 2024). Net loss: US$11.5m (loss narrowed by 76% from 2Q 2024). US$0.14 loss per share (improved from US$0.59 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Sutro Biopharma Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 63%. Looking ahead, revenue is expected to decline by 18% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%. Performance of the American Biotechs industry. The company's share price is broadly unchanged from a week ago. Risk Analysis It's necessary to consider the ever-present spectre of investment risk. We've identified 5 warning signs with Sutro Biopharma (at least 1 which is significant), and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-08-2025
- Business
- Yahoo
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +64.10%. A quarter ago, it was expected that this company would post a loss of $0.63 per share when it actually produced a loss of $0.91, delivering a surprise of -44.44%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Sutro Biopharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $63.75 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 293.54%. This compares to year-ago revenues of $25.71 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Sutro Biopharma shares have lost about 55.6% since the beginning of the year versus the S&P 500's gain of 7.9%. What's Next for Sutro Biopharma? While Sutro Biopharma has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Sutro Biopharma was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.24 on $14.66 million in revenues for the coming quarter and -$1.79 on $62.76 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, ANI Pharmaceuticals (ANIP), is yet to report results for the quarter ended June 2025. The results are expected to be released on August 8. This drugmaker is expected to post quarterly earnings of $1.38 per share in its upcoming report, which represents a year-over-year change of +35.3%. The consensus EPS estimate for the quarter has been revised 0.4% lower over the last 30 days to the current level. ANI Pharmaceuticals' revenues are expected to be $188.35 million, up 36.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sutro Biopharma, Inc. (STRO) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
29-06-2025
- Business
- Yahoo
Applications for Mission Beach whole home short-term rental licenses to reopen
SAN DIEGO (FOX 5/KUSI) — For the first time in nearly three years, San Diego is reopening the application process for short-term vacation rental licenses in one of its most popular beach communities. Starting Tuesday, July 1 at 10 a.m., the City of San Diego will begin accepting Tier 4 Short-Term Residential Occupancy (STRO) license applications for whole-home rentals in Mission Beach. These licenses apply to properties rented out more than 20 days per year in the Mission Beach Community Planning Area. This marks the first opportunity to apply since the city paused Tier 4 applications in November 2022, after quickly reaching capacity during the last application window. Since then, the city has only been processing applicants from a waitlist. The Tier 4 license reopening comes under the framework of the city's STRO Ordinance, adopted by the San Diego City Council and approved by the California Coastal Commission. The rules regulate short-term rentals of fewer than 30 consecutive days, aiming to strike a balance between vacation rentals and long-term housing availability. Cal Fire awards $5.9M in forest health research grants to tackle wildfires 'As a result of this ordinance, we have seen more housing return to the market for San Diego residents, while also providing options for visitors who want to stay in one of San Diego's many vibrant and diverse neighborhoods,' said District 2 Councilmember Jennifer Campbell, whose district includes the beach community. 'Especially in popular areas like Mission Beach, these regulations have protected the neighborhood quality of life, and I am grateful to all the hosts who have adapted to follow this new model for their rentals.' To be eligible, applicants must: Hold an active Transient Occupancy Tax certificate. Be current on all Rental Unit Business Taxes. The application period will remain open for 45 days, ending Aug. 15, 2025. Once closed, the city will conduct a random lottery to determine the processing order and assign waitlist positions, as required by the San Diego's Municipal Code. As explained by the city, existing license holders in lower tiers can apply to be considered for a Tier 4 license. If approved, they'll be required to cancel their current license. San Diego officials confirmed that this reopening does not impact the availability or application process for Tier 1–3 licenses. More information about all license tiers is available online. 'I am committed to continuing to foster a positive and respectful relationship between San Diego residents and visitors as we enter this next phase of licensing,' Campbell continued. For San Diegans and visitors alike, the renewed availability of these licenses could mean more vacation options along the coast — while the city maintains its goal of preserving housing for residents and protecting neighborhood character. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
16-03-2025
- Business
- Yahoo
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue: US$62.0m (down 60% from FY 2023). Net loss: US$227.5m (loss widened by 113% from FY 2023). US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023). Phase II: 1. Phase III: 1. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 2.1%. In the last 12 months, the only revenue segment was Development of Biopharmaceutical Products contributing US$62.0m. The largest operating expense was Research & Development (R&D) costs, amounting to US$239.5m (83% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$11.0m. Explore how STRO's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 46% from a week ago. It is worth noting though that we have found 4 warning signs for Sutro Biopharma (1 doesn't sit too well with us!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
